Kayentis

Health Care · Clinical Trial Software
Has an LEI
Lately:6 news stories in 90 daysFollow changes →

Facts

as of Nov 20, 2026

With a 95.9% recommendation rate in 2026, Kayentis is a trusted partner for biotech, emerging biopharma, and global pharmaceutical companies. Since 2005, Kayentis has supported pharma, biotechs, and CROs by capturing meaningful patient input.

Legal name
KAYENTIS SASactive
Headquarters
Meylan, France
Founded
2003
Employees
100–199French register · Dec 2024
Revenue
$23.2M2024 · French register (451664809)
Register numbers
SIREN 451664809
Official records
LEI 969500LK8GG5LPS1UR35

These are the key facts about Kayentis on Alion as of Nov 20, 2026. Kayentis is headquartered in Meylan, France. It was founded in 2003. It has raised $11.5M in 2 funding rounds. The latest round is Venture - Series Unknown of $7.6M, announced in 2026.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Legal entity active
Yes
Sanctions lists
OFAC SDN, EU consolidated · sanctionssearch.ofac.treas.gov ↗
No match
Phishing reports
OpenPhish, Phishing.Database · openphish.com ↗
None
Layoff notices
US WARN notices on file · dol.gov ↗
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Footprint

Hiring in 1 city in 1 country.

1Cities
1Countries
SiteTypeOpen rolesHires most forEngineering
Meylan FranceHeadquarters0
Source: office addresses in postings and company registers

Financials

Funding rounds, investors and revenue on record.

$23.2MRevenue2024
$11.5MTotal raised
Venture - Series UnknownLatest round
2Rounds and grants
Money by yearUSD, rounds and grants
2026$7.6M1 record
2016$3.9M1 record
Largest rounds and grants
Sources: funding announcements, grant and company registers

Money

Kayentis has $11.5M paid in by investors, lenders and donors.

$11.5MPaid in
StagePaidSignedAnnouncedSourceFiledAnnouncedPress
Money in
Equity raised
Oct 2026 · Venture round
$7.6MPaid
Equity raised
Oct 2016 · Venture round
$3.9MPaid
Taxes
No public tax figures for this company or its entities.
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".

Milestones

Each milestone is dated by its source: registers, filings, the press

Newsroom

Oct 202026
Blog
Despite recent estimates showing a 7.1% enrollment rate in cancer treatment trials, surpassing historical figures of less than 5%, the challenges of recruiting and retaining pati…
Oct 162026
Blog
A Phase 1 oncology study went from kick-off to go-live in just 5 weeks, offering valuable lessons for accelerating study start-up. How Kayentis Delivered eCOA Go-Live in Just 5 W…
Oct 92026
Blog
A PHASE 1 ONCOLOGY STUDY IN ADULTS WITH METASTATIC BONE PAINKayentis delivered the electronic solution for daily capture of:an NRS-based pain instrument supporting the primary ef…
Oct 92026
Blog
Home Go back White Paper CNS Turning endpoint noise into reliable CNS trial data Most CNS trials don't fail because the therapy doesn't work. They fail because assessment variabi…
Oct 42026
News · pharmaphorum
French tech company Kayentis has raised €7 million in private funding that will be invested in its digital platform for clinical trials
Oct 22026
Blog
Meet our colleague Anna Dudalyan at CTAD. Schedule a meeting L'article CTAD Clinical Trial on Alzheimer's Disesases est apparu en premier sur Kayentis.
Sources: the outlets named on each headline, each story once